Featured Research

from universities, journals, and other organizations

Resistance to TB Vaccine May Be Uncommon, Protects Against Nine Strains in Mice

Date:
November 28, 2008
Source:
American Society for Microbiology
Summary:
A new study shows that the current tuberculosis vaccine induces protective immunity against nine strains of the bacteria in mice indicating that strain-specific resistance may be uncommon.

A new study shows that the current tuberculosis vaccine induces protective immunity against nine strains of the bacteria in mice indicating that strain-specific resistance may be uncommon.

Tuberculosis (TB) is one of the world's most challenging infectious diseases to date and is responsible for approximately 2 million deaths per year. An attenuated vaccine incorporating Mycobacterium bovis BCG has been used for over 50 years, however, high mortality rates have persisted and researchers attribute multiple factors to its varying effectiveness including that the anti-TB protective immunity induced by the vaccine may be strain-specific.

W-Beijing lineage strains are among the most prominent associated with worldwide outbreaks of TB. In the study researchers investigated the strain specificity of Mycobacterium bovis BCG vaccine-induced antituberculosis protective immunity responses by inoculating mice with the vaccine and challenging them 2 months later with one of nine Mycobacterium tuberculosis strains, four from the W-Beijing lineage, four non-Beijing isolates, and one control.

Organ bacterial burdens and lung pathology were examined in vaccinated and naοve mice the day of infection as well as at 4, 12, and 20 weeks postchallenge. Four weeks following an aerosol challenge with each of the strains, results showed the bacterial growth in the lungs and spleens were much lower and lung pathology significantly improved in all vaccinated animals when compared to controls. Animals infected with six of the nine strains exhibited reduced organ bacterial burdens after 12 weeks and lung inflammation in all immunized animals was measurably lower at 20 weeks postchallenge.

"These data demonstrate that BCG vaccination protects against infection with diverse M. tuberculosis strains in the mouse model of pulmonary tuberculosis and suggest that strain-specific resistance to BCG-induced protective immunity may be uncommon," say the researchers.


Story Source:

The above story is based on materials provided by American Society for Microbiology. Note: Materials may be edited for content and length.


Journal Reference:

  1. (B.Y. Joen, S.C. Derrick, J. Lim, K. Kolibab, V. Dheenadhayalan, A.L. Yang, B. Kreiswirth, S.L. Morris. Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice. Infection and Immunity, 76. 11: 5173-5180

Cite This Page:

American Society for Microbiology. "Resistance to TB Vaccine May Be Uncommon, Protects Against Nine Strains in Mice." ScienceDaily. ScienceDaily, 28 November 2008. <www.sciencedaily.com/releases/2008/11/081125161535.htm>.
American Society for Microbiology. (2008, November 28). Resistance to TB Vaccine May Be Uncommon, Protects Against Nine Strains in Mice. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2008/11/081125161535.htm
American Society for Microbiology. "Resistance to TB Vaccine May Be Uncommon, Protects Against Nine Strains in Mice." ScienceDaily. www.sciencedaily.com/releases/2008/11/081125161535.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) — Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) — Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) — Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins